TABLE 5.
Neutralization sensitivity of epitope-masked Env chimeras containing different V3 domains
| V3 sequencea | IC50 (μg/ml)b
|
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-V3B MAbs
|
Anti-V3A MAbs
|
|||||||||||||
| 2219 | 2456 | 4148 | 447-D | 2191 | 2442 | 4117 | 2412 | 3074 | 2557 | 2558 | 3019 | 2601 | 2182 | |
| Subtype B cons | 0.62 | 2.9 | 7.7 | 0.57 | 1.0 | 0.56 | 5.3 | 12 | 11 | 1.8 | 3.5 | 6.3 | >50 | 0.88 |
| Subtype A1 cons | 100 | >100 | >100 | >100 | >100 | 37 | >100 | >100 | 22 | 91 | 53 | 74 | 42 | >100 |
| Subtype C cons | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | 67 | >100 | 71 | >100 | >50 | >100 |
| CRF02_AG cons | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | 41 | >100 | >100 | >100 | >50 | >100 |
a
cons, consensus.
b
IC50s for anti-V3 MAbs against viruses pseudotyped with SF162 Env in which the V1/V2 domain was replaced with that of JR-FL V1/V2 and the V3 domain was replaced with the indicated V3 consensus sequences. Samples with no discernable neutralization at the highest MAb concentration tested (50 or 100 μg/ml) are in bold. Data for the masked Env with the subtype B V3 sequence are from Table 2.